Human Genome Epidemiology Literature Finder
|
Records 1 - 13 (of 13 Records) |
| Query Trace: Osteosarcoma and MTHFR[original query] |
|---|
| Methylenetetrahydrofolate reductase C677T gene polymorphism in osteosarcoma and chondrosarcoma patients. Folia biologica 2008 54 (2): 53-7. Ozger H, Kilicoglu O, Yilmaz H, Ergen H A, Yaylim I, Zeybek U, Isbir |
| Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. The Journal of pediatrics 2009 May 154 (5): 688-93. Patiño-García Ana, Zalacaín Marta, Marrodán Lucía, San-Julián Mikel, Sierrasesúmaga Lu |
| Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 2012 Apr 118 (7): 1856-67. Windsor Rachael E, Strauss Sandra J, Kallis Constantinos, Wood Nicholas E, Whelan Jeremy |
| Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pacific journal of cancer prevention : APJCP 2012 13 (4): 1553-6. Dogan Mutlu, Karabulut Halil G, Tukun Ajlan, Demirkazik Ahmet, Utkan Gungor, Yalcin Bulent, Dincol Dilek, Akbulut Hakan, Icli Fik |
| Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. The pharmacogenomics journal 2015 Oct 15 (5): 385-90. Jabeen S, Holmboe L, Alnæs G I G, Andersen A M, Hall K S, Kristensen V |
| Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood research 2016 Mar 51 (1): 50-7. Park Jeong A, Shin Hee You |
| The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. Pharmacogenomics 2017 Jun . Lambrecht Loes, Sleurs Charlotte, Labarque Veerle, Dhooge Catharina, Laenen Annouschka, Sinnaeve Friedl, Renard Marleen, Uyttebroeck An |
| ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. Journal of pediatric hematology/oncology 2017 Mar . Park Jeong A, Shin Hee You |
| More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate. Oncotarget 2018 Feb 9 (14): 11465-11476. Xie Lu, Guo Wei, Yang Yi, Ji Tao, Xu J |
| MTHFR variant is associated with high-dose methotrexate-induced toxicity in the Chinese osteosarcoma patients. Journal of bone oncology 2018 Nov 13 143-147. Xu Leilei, Wang Lujun, Xue Bingchuan, Wang Shoufe |
| Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. Journal of clinical pharmacy and therapeutics 2021 Aug . Gong Yan, Luo Li, Wang Liu, Chen Jun, Chen Fen, Ma Yuanyuan, Xu Zhen, Sun Yiqi, Luo Lin, Shi Chen, Li Xinga |
| The Role of Single Nucleotide Polymorphisms in Transporter Proteins and the Folate Metabolism Pathway in Delayed Methotrexate Excretion: A Case Report and Literature Review. Pharmacogenomics and personalized medicine 2022 11 15 919-926. Wang Jun, Zhao Yue-Tao, Sun Meng-Jiao, Chen Feng, Guo Hong- |
| MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment. Frontiers in oncology 2022 1 11 781386. Zhang Wenchao, Liu Zhongyue, Yang Zhimin, Feng Chengyao, Zhou Xiaowen, Tu Chao, Li Zhiho |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: